TESARO, Inc. stock performance trend indicates that the stock price has rallied 7.24% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 49.63% . Looking at the past 52 week period, the stock price is up at 230.45% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of TESARO, Inc. has a positive value of 292.95 compared to overall market.Tesaro, Inc. is having a Relative Strength Index of 29.94 which indicates the stock is not yet over sold or over bought based on the technical indicators.
TESARO, Inc. (NASDAQ:TSRO) has tumbled 13.45% during the past week and has dropped 21.21% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 13.66%. TESARO, Inc. (NASDAQ:TSRO) has underperformed the index by 22.11% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
For the current week, the company shares have a recommendation consensus of Buy. TESARO, Inc. (NASDAQ:TSRO) stock ended Friday session in the red zone in a volatile trading. The stock closed down 3.26 points or 2.13% at $149.99 with 1,631,804 shares getting traded. Post opening the session at $152.66, the shares hit an intraday low of $149.7 and an intraday high of $153.12 and the price was in this range throughout the day. The company has a market cap of $8,043 million and the number of outstanding shares has been calculated to be 53,626,219 shares. The 52-week high of TESARO, Inc. (NASDAQ:TSRO) is $192.94 and the 52-week low is $36.68.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.TESARO Inc was Reiterated by Wedbush on Mar 15, 2017 to Outperform, Lowers Price Target to $ 164 from a previous price target of $200 .Company shares were Downgraded by Robert W. Baird on Feb 27, 2017 to Neutral, Raises Price Target to $ 182 from a previous price target of $127 .Company shares were Reiterated by RBC Capital Mkts on Feb 17, 2017 to Outperform, Raises Price Target to $ 202 from a previous price target of $142 .Company shares were Downgraded by FBR & Co. on Feb 16, 2017 to Mkt Perform, Raises Price Target to $ 202 from a previous price target of $151 .TESARO Inc was Downgraded by Leerink Partners to Mkt Perform on Feb 10, 2017.
Company has reported several Insider transactions to the SEC, on Mar 8, 2017, Edward C English (V.P. of Finance & Admin.) sold 10,000 shares at 178.06 per share price.On Mar 3, 2017, Timothy R Pearson (Exec. VP, CFO) sold 1,447 shares at 177.61 per share price.On Mar 3, 2017, Orlando Oliveira (SVP & GM, International) sold 249 shares at 177.61 per share price.
TESARO Inc Last issued its quarterly earnings results on Feb 28, 2017. The company reported $-2.60 EPS for the quarter, missing the analyst consensus estimate by $ -0.71. Analyst had a consensus of $-1.89. The company had revenue of $4.20 million for the quarter, compared to analysts expectations of $4.69 million. The companys revenue was up 1726.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.89 EPS.
Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Companys product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts.